简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

Bionano Genomics报告第四季度业绩

2026-03-24 04:11

  • Bionano Genomics press release (BNGO): Q4 net loss of $8M.
  • Revenue of $8M (-2.4% Y/Y) beats by $0.12M.
  • Sold 7,554 nanochannel array flowcells in the fourth quarter of 2025, representing a decrease of 6% over the 8,058 flowcells sold in the fourth quarter of 2024.
  • Initiating Q1 2026 revenue guidance in the range of $6.5M to $6.7M vs consensus revenue of $7.15M.
  • Initiating full-year 2026 revenue guidance in the range of $30M to $33M vs consensus revenue of $34.55M.

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。